Rocket sells FDA voucher for $180M cash boost
Rocket Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company for $180 million in gross, non-dilutive proceeds.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Rocket Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company for $180 million in gross, non-dilutive proceeds. The voucher was granted following FDA approval of KRESLADI, Rocket’s gene therapy for severe leukocyte adhesion deficiency-I.
Rocket previously reported cash, cash equivalents and investments of $144.4 million as of March 31, 2026. Pro forma for the voucher sale, this increases to about $322.6 million, which the company expects will fund operations into the second quarter of 2028.
Positive
- Rocket monetizes PRV for $180 million in non-dilutive cash, significantly strengthening its balance sheet without issuing new shares.
- Pro forma cash, cash equivalents and investments rise to approximately $322.6 million from $144.4 million, which the company expects will fund operations into the second quarter of 2028.
Negative
- None.
Insights
$180M PRV sale more than doubles Rocket’s cash and extends runway.
Rocket Pharmaceuticals monetized its Rare Pediatric Disease Priority Review Voucher for $180 million in gross proceeds. This is characterized as non-dilutive, meaning existing shareholders are not diluted by new equity issuance to obtain this capital.
As of March 31, 2026, Rocket reported $144.4 million in cash, cash equivalents and investments. Pro forma for this transaction, the balance rises to roughly $322.6 million, and management states this is expected to fund operations into the second quarter of 2028, providing a longer planning horizon for its gene therapy pipeline.
The sale follows FDA approval of KRESLADI for severe leukocyte adhesion deficiency-I, which generated the voucher. Future filings and updates on clinical timelines and spending priorities will help clarify how this extended runway supports Rocket’s cardiovascular and immunology programs.
8-K Event Classification
3 items: 2.01, 7.01, 9.01
3 items
Item 2.01
Completion of Acquisition or Disposition of Assets
Financial
The company completed a significant acquisition or sale of business assets.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
PRV sale proceeds: $180.0 million
Cash before PRV sale: $144.4 million
Pro forma cash after PRV sale: Approximately $322.6 million
+3 more
6 metrics
PRV sale proceeds
$180.0 million
Gross proceeds received upon closing of asset sale
Cash before PRV sale
$144.4 million
Cash, cash equivalents and investments as of March 31, 2026
Pro forma cash after PRV sale
Approximately $322.6 million
Pro forma cash, cash equivalents and investments after voucher sale
Cash runway
Into Q2 2028
Company expectation for funding operations with pro forma cash
PRV grant timing
March 2026
FDA granted Rare Pediatric Disease Priority Review Voucher with KRESLADI approval
8-K event date
June 10, 2026
Completion date of PRV asset sale
Key Terms
Rare Pediatric Disease Priority Review Voucher, biologics license application, autologous hematopoietic stem cell-based gene therapy, forward-looking statements, +1 more
5 terms
Rare Pediatric Disease Priority Review Voucher regulatory
"sale of its Rare Pediatric Disease Priority Review Voucher ("PRV") to a large pharmaceutical company"
A rare pediatric disease priority review voucher is a transferable regulatory benefit awarded to a company that wins approval for a drug treating a serious but uncommon childhood illness. It works like a “fast-pass” with regulators: the holder can use it to get an accelerated review of a future drug application or sell the voucher to another company, often for a large sum. Investors care because it can speed time to market or generate immediate cash, boosting potential returns and lowering risk on other programs.
biologics license application regulatory
"issued in connection with the FDA’s approval of the Company’s biologics license application for KRESLADI™"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
autologous hematopoietic stem cell-based gene therapy medical
"an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients"
A treatment that takes a patient’s own blood-forming stem cells, modifies their genes outside the body to correct or add a function, and then returns those altered cells to the same patient so they can rebuild a healthy blood and immune system. Investors care because it is a personalized, potentially one-time therapy with high development and manufacturing costs but the promise of long-term benefit, which can mean large up-front pricing, specialized production facilities, and regulatory risk and reward similar to a custom-built product.
forward-looking statements regulatory
"This press release contains forward-looking statements concerning Rocket’s future expectations, plans and prospects"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
cash, cash equivalents and investments financial
"before the PRV sale Rocket had cash, cash equivalents and investments of $144.4 million"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transaction did Rocket Pharmaceuticals (RCKT) announce in this 8-K?
Rocket Pharmaceuticals completed the sale of its Rare Pediatric Disease Priority Review Voucher to a large pharmaceutical company for $180 million in gross proceeds. The voucher came from FDA approval of KRESLADI, Rocket’s gene therapy for severe leukocyte adhesion deficiency-I.
How much cash did Rocket Pharmaceuticals (RCKT) receive from the PRV sale?
Rocket received $180 million in gross proceeds from selling its Rare Pediatric Disease Priority Review Voucher. The company describes these proceeds as non-dilutive, meaning they were generated without issuing additional equity to investors.
What is Rocket Pharmaceuticals’ (RCKT) pro forma cash position after the PRV sale?
Before the PRV sale, Rocket reported $144.4 million in cash, cash equivalents and investments as of March 31, 2026. Pro forma for the $180 million voucher sale, this balance increases to approximately $322.6 million according to the company’s disclosure.
How long does Rocket Pharmaceuticals (RCKT) expect its cash to last after this transaction?
With pro forma cash, cash equivalents and investments of about $322.6 million, Rocket states it expects to fund operations into the second quarter of 2028. This extended runway supports ongoing development of its genetic therapy pipeline.
What product led to the Rare Pediatric Disease Priority Review Voucher at Rocket (RCKT)?
The voucher was granted by the FDA in connection with approval of KRESLADI™, Rocket’s autologous hematopoietic stem cell-based gene therapy for severe leukocyte adhesion deficiency‑I, a rare and life-threatening primary immunodeficiency in pediatric patients.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 10, 2026
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
|
(Address of principal
executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (609 )
659-8001
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2):
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.01. |
Completion of Acquisition or Disposition of Assets.
|
On June 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) completed the previously disclosed sale (the “Asset Sale”) of its Rare Pediatric
Disease Priority Review Voucher (“PRV”) to a large pharmaceutical company. The PRV was originally issued in connection with the FDA’s approval of the Company’s biologics license application for KRESLADI™ (marnetegragene autotemcel), an autologous
hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion deficiency-I (LAD-I) due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling donor
for allogeneic hematopoietic stem cell transplant.
The Asset Sale was completed pursuant to the terms of an asset purchase agreement, dated April 26, 2026 (the “PRV APA”). Pursuant to the PRV APA, the
Company received gross proceeds of $180.0 million from the buyer upon the closing of the Asset Sale.
The foregoing description of the PRV APA does not purport to be complete and is subject to, and qualified in its entirety, by the full text of the
PRV APA, a copy of which will be filed with Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026. The representations, warranties, covenants and agreements contained in the PRV APA were made only for the purposes of
the PRV APA and as of specific dates, are solely for the benefit of the parties to the PRV APA, and may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures. The representations and warranties
in the PRV APA were made for the purpose of allocating contractual risk between the parties to the PRV APA instead of establishing these matters as facts. Accordingly, the representations and warranties in the PRV APA are not intended to, and do
not, constitute representations and warranties to any person other than the parties to the PRV APA, including investors and security holders, and should not be relied upon as statements of factual information.
| Item 7.01. |
Regulation FD Disclosure.
|
On June 12, 2026, the Company issued a press release announcing the closing of the Asset Sale, a copy
of the which is furnished as Exhibit 99.1 hereto.
The information under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act, except as shall
be expressly set forth by specific reference in such filing.
| Item 9.01. |
Financial Statements and Exhibits.
|
| (d) |
Exhibits.
|
|
99.1
|
Press Release of Rocket Pharmaceuticals, Inc. dated June 12, 2026.
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
Rocket Pharmaceuticals, Inc.
|
||
|
Date: June 12, 2026
|
By:
|
/s/ Martin Wilson
|
|
Martin Wilson
|
||
|
General Counsel and Chief Corporate Officer
|
||
Exhibit 99.1
Rocket Pharmaceuticals Announces Closing of Sale of
Rare Pediatric Disease Priority Review Voucher for $180 Million
CRANBURY, NJ – June 12, 2026 – Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company
advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million.
The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket’s gene therapy for severe
leukocyte adhesion deficiency-I (LAD-I), a rare and life-threatening primary immunodeficiency.
As previously reported, before the PRV sale Rocket had cash, cash equivalents and
investments of $144.4 million as of March 31, 2026. Following the $180 million in non-dilutive proceeds from the PRV sale, pro forma cash, cash equivalents and
investments increased to approximately $322.6 million, which the Company expects to fund operations into the second quarter of 2028.
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated biotechnology company advancing gene therapies for rare and devastating cardiovascular diseases, with
additional programs in hematology and immunology. Rocket’s cardiovascular pipeline includes three clinical stage programs that each target one of the major inherited cardiomyopathy subtypes: hypertrophic, arrhythmogenic, and dilated
cardiomyopathies. Together these conditions represent more than 100,000 patients in the U.S. and EU. The Company’s platform is supported by proprietary AAV manufacturing capabilities, multi-year efficacy and safety data in cardiac gene therapy, and
experience treating several cardiac patients across late-stage AAV programs. For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X.
Rocket Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements concerning Rocket’s future expectations, plans and prospects that involve risks and uncertainties, as well as
assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance
on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of
those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket’s cash runway and financial position, Rocket’s planned use of proceeds from the monetization of the KRESLADI™ PRV, Rocket’s expectations of
our ability to obtain additional funding to conduct our planned research and development efforts, the expected timing and data readouts of Rocket’s ongoing and planned clinical trials, the expected timing and outcome of Rocket’s regulatory
interactions and planned submissions, Rocket’s plans for the advancement of its cardiovascular AAV programs and KRESLADI™, including its planned pivotal trials, and the safety, effectiveness and timing of related pre-clinical studies and clinical
trials, Rocket’s ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates and Rocket’s ability to expand its pipeline to target additional indications that are
compatible with its gene therapy technologies. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various important factors, including, without limitation, the results of Rocket’s ongoing and planned clinical trials, Rocket’s dependence on third parties for development, manufacture,
marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket’s competitors’ activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket’s
ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, Rocket’s ability to acquire additional businesses, form strategic alliances or create joint
ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, our ability to achieve the expected benefits of our portfolio prioritization and strategic restructuring, including extending our cash runway,
Rocket’s ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled "Risk
Factors" in Rocket’s Annual Report on Form 10-K for the year ended December 31, 2025, filed February 26, 2026 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue
reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events
or otherwise.
Investors
Meg Dodge
mdodge@rocketpharma.com
Media
Kevin Giordano
media@rocketpharma.com